David Siegel
Physician · Regional Cancer Care Associates LLC
Credentials: · · · ·
History
- Present
Regional Cancer Care Associates LLC
Research
A phase 2 study of bortezomib in relapsed, refractory myeloma
New England Journal of Medicine · 2003 · 2,206 citations
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
New England Journal of Medicine · 2021 · 2,130 citations
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2019 · 1,419 citations
71 papers
68 papers
42 papers
- BB
36 papers
34 papers
30 papers
30 papers
- AJ
28 papers
Clinical trials
- 2026–2028
Principal investigator · Not yet recruiting
Hackensack Meridian Health
- 2011–2016
Principal investigator · Completed · Phase 1, Phase 2
Hackensack Meridian Health
- 2011–2027
Principal investigator · Active not recruiting · Phase 1, Phase 2
Hackensack Meridian Health
- 2005–2007
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
Principal investigator · Completed · Phase 1
Infinity Pharmaceuticals, Inc.